NCT07929857
Effectiveness and Safety of Cellbooster Hair in Healthy Subjects
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Change from baseline of hair density (total number of hair in the studied zone) at Day 130 evaluated by Phototrichogram (PTG) analysis
Timeframe: Day 130
Secondary (14)
Change from baseline of hair diameter at Day 130 evaluated by Phototrichogram (PTG) analysis
Change from baseline of hair loss at Day 130 evaluated by Phototrichogram (PTG) analysis : percentage of telogen hair (%T)
Change from baseline of hair loss at Day 130 evaluated by Phototrichogram (PTG) analysis : anagen hair density (DA), telogen hair density (DT)
Change from baseline of hair loss at Day 130 evaluated by Phototrichogram (PTG) analysis : anagen to telogen ratio (DA/DT)
Change from baseline of hair average roughness (Ra), quadratic mean (Rq), maximum relief amplitude (Rt) and average relief (Rz) at Day 130 evaluated by MiniSurf® (only on subjects with hair length>10 cm).
Show 9 moreShow less
Change from baseline of scalp skin hydration at Day 35 and Day 130 evaluated by Corneometer® on shaved area.
Change from baseline of scalp skin trans epidermal water loss (TEWL) at Day 35 and Day 130 evaluated by Aquaflux® on shaved area.
Change from baseline of scalp dermis thickness and density (ratio non-echogenic surface/total surface) at Day 35 and Day 130 evaluated by DermaScan® 2D on shaved area.
Proportion of subjects having an improvement with CBH treatment as assessed by the investigator at Day 35 and Day 130, using the Investigator Global Assessment (IGA).
Illustration of the device effect on hair loss with standardized photos of the vertex and after standardized shampoo/cut/brush at Day 0, Day 35 and Day 130.
Degree of satisfaction of the injectors through the answers to a subjective evaluation questionnaire completed for each subject after each three injection session (Day 28 and Day 70).
Degree of satisfaction of the subjects through the answers to a subjective evaluation questionnaire at Day 35 and Day 130. For each question, the percentage of subject satisfied, (percentages of answers "agree" or "totally agree") will be computed.
Number of Injection Site Reactions (ISRs) by the investigator on the scalp, before and immediately after each injection session (Day 0, Day 14, Day 28, Day 35, Day 42, Day 56, Day 70 and Day 130).
Number of adverse events (AEs) and concomitant treatments during the study.
Arms and interventions
CBHExperimental
Devices: Scalp booster injection (CBH)
Sites
2 sites in 1 country